China Healthcare Weekly(Sep.21)-HK Biotechs Are Overvalued, Duality, Story Behind "Crazy" TransThera
​Investors in HK biotechs should consider taking profits as they are overvalued. Duality is under pressure of correction. TransThera’s shares...
607 Views
TransThera Sciences (Nanjing)Â IPO: Uniqueness of Lead Candidate Provides Comfort for Long-Term
TransThera Sciences got Phase 2 clinical trial approval for its lead drug candidate, Tinengotinib in combination with Fulvestrant for the treatment...
665 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
575 Views
China Healthcare Weekly (Nov.16) - Crazy Healthcare IPOs, Don't Bet on BD, Biokin HK IPO Delayed
​Investors're advised to focus on technical route over new BD deals from Chinese companies. Investors need to remain rational about healthcare...
317 Views
HK Strategy: Who Will Suffer the Most?
​Trump's tariff threats and market uncertainty lead to a potential heavy sell-off in HK, with top-performing stocks like SMIC, Kuaishou, Alibaba,...
347 Views